Related Experiment Videos
[Pathophysiology of collateral coronary circulation]
J Pogorzelska-Dyrbuś1, K Dyrbuś
1I Katedry i Zakładu Histologii i Embriologii Slaskiej Akademii Medycznej w Katowicach.
Insights
Collateral circulation in the heart, involving vasculogenesis and angiogenesis, can mitigate coronary artery occlusion. Future therapies may involve stimulating this process for ischemic heart disease treatment.
Area of Science:
- Cardiovascular Biology
- Vascular Biology
- Ischemic Pathophysiology
Context:
- Coronary artery occlusion can lead to severe myocardial damage.
- Collateral vessels offer a protective mechanism against ischemic events.
- Understanding collateral growth is crucial for managing heart disease.
Purpose:
- To elucidate the mechanisms of cardiac collateral circulation development.
- To explore the role of growth factors and ischemia in promoting collateral growth.
- To discuss the therapeutic potential of stimulating angiogenesis in ischemic heart disease.
Summary:
- Cardiac collateral circulation involves two primary growth mechanisms: vasculogenesis and angiogenesis.
- These processes are initiated by ischemia and mediated by peptide growth factors, often produced in inflammatory tissues.
- The study details the cellular events, including mitosis and migration of endothelial and smooth muscle cells.
Impact:
- Highlights the protective role of collateral vessels in reducing the severity of coronary artery occlusion.
- Suggests that therapeutic angiogenesis, though controversial, holds future promise for treating ischemic heart disease.
- Provides insights into the molecular triggers and cellular processes underlying collateral development.
Abstract:
The study presents the concepts of collateral circulation in the heart. These vessels can reduce the fatal consequences of occlusion of large coronary artery. There are described two mechanisms of its growth: vasculogenesis (mitosis of endothelial cells, and smooth muscle cells), and angiogenesis (migration and mitosis of endothelial cells). These processes are triggered by ischemia and by expression of peptide growth factors. Growth factors are produced by macrophages and often are found in inflammation tissue. Therapeutic angiogenesis remains controversial, however in the near future stimulation of angiogenesis by peptides, drugs and gene therapy will have a place in therapy of ischemic heart disease.